Natera and BGI Genomics announce commercial launch of the BGI/Natera Signatera assay in China (Natera Press Release)
"Natera, Inc...and BGI Genomics Co., Ltd...today announced the launch of the BGI/Natera Signatera Assay which is now available to biopharmaceutical customers and clinicians across China...Natera’s Signatera® assay, now offered in partnership with BGI,1 has been utilized in numerous clinical studies across non-small cell lung, bladder, breast and colorectal cancers, to identify molecular residual disease (MRD) up to two years earlier than standard imaging. The test is now available in China under the Chinese brand name "Tumor MRD Customized Detection (HuaJianWei® for short)."